Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Summary: Background: The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | The Lancet Global Health |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214109X19304826 |
| _version_ | 1819168857387958272 |
|---|---|
| author | Marc Arbyn, PhD Elisabete Weiderpass, PhD Laia Bruni, MD Silvia de Sanjosé, PhD Mona Saraiya, MD Jacques Ferlay, Ir Freddie Bray, PhD |
| author_facet | Marc Arbyn, PhD Elisabete Weiderpass, PhD Laia Bruni, MD Silvia de Sanjosé, PhD Mona Saraiya, MD Jacques Ferlay, Ir Freddie Bray, PhD |
| author_sort | Marc Arbyn, PhD |
| collection | DOAJ |
| description | Summary: Background: The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative. Methods: For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis. Findings: Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed. Interpretation: Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening—including self-sampling—has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem. Funding: Belgian Foundation Against Cancer, DG Research and Innovation of the European Commission, and The Bill & Melinda Gates Foundation. |
| first_indexed | 2024-12-22T19:10:16Z |
| format | Article |
| id | doaj.art-844b538f5839414b87348bcc0cd5c3ed |
| institution | Directory Open Access Journal |
| issn | 2214-109X |
| language | English |
| last_indexed | 2024-12-22T19:10:16Z |
| publishDate | 2020-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Global Health |
| spelling | doaj.art-844b538f5839414b87348bcc0cd5c3ed2022-12-21T18:15:42ZengElsevierThe Lancet Global Health2214-109X2020-02-0182e191e203Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysisMarc Arbyn, PhD0Elisabete Weiderpass, PhD1Laia Bruni, MD2Silvia de Sanjosé, PhD3Mona Saraiya, MD4Jacques Ferlay, Ir5Freddie Bray, PhD6Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium; Correspondence to: Dr Marc Arbyn, Unit of Cancer Epidemiology, Belgian Cancer Centre, B1050 Brussels, BelgiumInternational Agency for Research on Cancer, Lyon, FranceConsortium for Biomedical Research in Epidemiology and Public Health, Barcelona, Spain; Unit of Infections and Cancer, Catalonian Institute of Oncology, Barcelona, SpainPATH, Seattle, WA, USACenters for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USAInternational Agency for Research on Cancer, Lyon, FranceInternational Agency for Research on Cancer, Lyon, FranceSummary: Background: The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative. Methods: For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis. Findings: Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed. Interpretation: Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening—including self-sampling—has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem. Funding: Belgian Foundation Against Cancer, DG Research and Innovation of the European Commission, and The Bill & Melinda Gates Foundation.http://www.sciencedirect.com/science/article/pii/S2214109X19304826 |
| spellingShingle | Marc Arbyn, PhD Elisabete Weiderpass, PhD Laia Bruni, MD Silvia de Sanjosé, PhD Mona Saraiya, MD Jacques Ferlay, Ir Freddie Bray, PhD Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis The Lancet Global Health |
| title | Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis |
| title_full | Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis |
| title_fullStr | Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis |
| title_full_unstemmed | Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis |
| title_short | Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis |
| title_sort | estimates of incidence and mortality of cervical cancer in 2018 a worldwide analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2214109X19304826 |
| work_keys_str_mv | AT marcarbynphd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT elisabeteweiderpassphd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT laiabrunimd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT silviadesanjosephd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT monasaraiyamd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT jacquesferlayir estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis AT freddiebrayphd estimatesofincidenceandmortalityofcervicalcancerin2018aworldwideanalysis |